Skip to Content
Merck
  • Differential acetylcholine and choline concentrations in the cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia.

Differential acetylcholine and choline concentrations in the cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia.

Chinese medical journal (2004-09-14)
Jian-ping Jia, Jian-min Jia, Wei-dong Zhou, Min Xu, Chang-biao Chu, Xin Yan, Yong-xin Sun
ABSTRACT

An important aspect of Alzheimer's disease (AD) is loss or impairment of cholinergic neurons. It is controversial whether there is a similar cholinergic impairment and cerebral deficit of acetylcholine (ACh) in the case of vascular dementia (VD). The purpose of this study was to explore the levels of ACh and choline (Ch) in the cerebrospinal fluid (CSF) of patients with AD and VD, and their possible relationship with cognitive impairment. Twenty-two AD patients, twenty-two VD patients, and twenty normal controls were recruited and scored with a Mini-Mental State Examination (MMSE). CSF concentrations of ACh and Ch were measured using high-performance liquid chromatography with an electrochemical detector (HPLC-ECD) and the results were then compared to cognitive status. ACh concentrations in CSF of AD patients [(10.7 +/- 5.1) nmol/L] and VD patients [(16.8 +/- 7.4) nmol/L] were both significantly lower than in controls [(34.5 +/- 9.0) nmol/L, t = 10.67, P < 0.001; t = 6.91, P < 0.001]. Both results correlated positively with MMSE scores (rs = 0.88 and rs = 0.85, respectively, P < 0.01). The CSF concentration of Ch was significantly higher in VD patients [(887.4 +/- 187.4) nmol/L] compared to AD patients [(627.6 +/- 145.1) nmol/L, t = 6.4, P < 0.001] and controls [(716.0 +/- 159.4) nmol/L, t = 4.2, P = 0.002]. CSF Ch concentration showed no difference between AD patients and normal controls, nor did it correlate with MMSE score in any of the three groups. The positive correlation between ACh deficit and cognitive impairment suggests that ACh is an important neurotransmitter for memory. The similar decrease in ACh concentration in AD and VD patients may imply a similar pathogenesis for the process of cognitive impairment involved in these two disorders. The elevated CSF levels of Ch in VD patients compared to AD patients may be useful diagnostically. Cholinesterase inhibitors may be helpful not only for AD patients, but also for VD patients.

MATERIALS
Product Number
Brand
Product Description

Supelco
Glycine, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
Zinc preparation, 5 g/dL Zn2+ in THF, highly reactive Rieke®metal
Sigma-Aldrich
Magnesium preparation, Highly Reactive Rieke® Metal, suspension, 2.5 g in THF
Sigma-Aldrich
Gly-Pro
Sigma-Aldrich
L-Cystathionine, ≥98% (TLC)
Sigma-Aldrich
Magnesium, ribbon, ≥99.0% Mg basis
Aluminum, IRMM®, certified reference material, 1.0 mm wire
Aluminum, IRMM®, certified reference material, 1.0 mm foil
Titanium, IRMM®, certified reference material, 0.5 mm wire
Titanium, IRMM®, certified reference material, 0.5 mm foil
SAFC
L-Aspartic acid
SAFC
L-Cystine
SAFC
L-Tyrosine
SAFC
L-Threonine
SAFC
L-Valine
SAFC
L-Proline
SAFC
Glycine
Sigma-Aldrich
Glycine, ACS reagent, ≥98.5%
Sigma-Aldrich
L-Tyrosine, FG
Continuous cast copper (O), BCR®, certified reference material, rod
Sigma-Aldrich
L-Glutamine solution, 200 mM, Hybri-Max, sterile-filtered, suitable for hybridoma
SAFC
L-Glutamine Solution 200 mM, 29.23 mg/mL in saline, solution, suitable for cell culture
Sorbitol, European Pharmacopoeia (EP) Reference Standard
Mannitol, European Pharmacopoeia (EP) Reference Standard
Supelco
Methylmalonic acid solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
L-Proline, ReagentPlus®, ≥99% (HPLC)
Sigma-Aldrich
Magnesium, in a Sure/Seal bottle, turnings, anhydrous tetrahydrofuran 37.5 mmol
Sigma-Aldrich
L-Valine, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
3,4-Dihydroxyphenylacetic acid, 98%
Sigma-Aldrich
Adonitol, ≥99%